Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses

Objective

Although sorafenib plus transcatheter arterial chemoembolization (SoraTACE) has been widely applied for advanced hepatocellular carcinoma (HCC) in most Asian countries, sorafenib plus hepatic arterial infusion chemotherapy (SoraHAIC) may be a better alternative. This phase III trial assessed the efficacy and safety of SoraHAIC versus SoraTACE in patients with advanced HCC.